Jane Street’s ADMA Biologics ADMA Stock Holding History

Jane Street’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$471K	Buy	56,300 +36,000	+177%	+$328K	﹤0.01%	8154
2026 Q1	$183K	Sell	20,300 -41,900	-67%	-$661K	﹤0.01%	10235
2025 Q4	$1.13M	Sell	62,200 -90,400	-59%	-$1.52M	﹤0.01%	5865
2025 Q3	$2.24M	Buy	152,600 +101,300	+197%	+$1.74M	﹤0.01%	4735
2025 Q2	$934K	Buy	51,300 +18,000	+54%	+$367K	﹤0.01%	5743
2025 Q1	$661K	Buy	+33,300	New	+$576K	﹤0.01%	6352
2023 Q3	–	Sell	-53,400	Closed	-$197K	–	8535
2023 Q2	$197K	Buy	53,400 +1,200	+2%	+$4.45K	﹤0.01%	7687
2023 Q1	$173K	Buy	+52,200	New	+$180K	﹤0.01%	7936
2022 Q1	–	Sell	-22,700	Closed	-$32K	–	10189
2021 Q4	$32K	Buy	22,700 +2,300	+11%	+$3.02K	﹤0.01%	9676
2021 Q3	$23K	Buy	20,400 +2,100	+11%	+$2.94K	﹤0.01%	9730
2021 Q2	$29K	Buy	+18,300	New	+$32.2K	﹤0.01%	9598

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jane Street's ADMA Position: Q2 2026 in Review

Jane Street reduced its ADMA Biologics (ADMA) stake by 78% in Q2 2026, selling an estimated $21.8M and leaving 662,082 shares worth $5.54M. The position accounts for ﹤0.01% of the portfolio, ranked #3563.

Jane Street first reported a position in ADMA in Q1 2019 and has held it in 26 quarters since. The position peaked at $27.5M in Q1 2026. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Jane Street held 662,082 shares of ADMA Biologics worth $5.54M as of Q2 2026.
Jane Street sold 2,389,861 ADMA Biologics shares in Q2 2026, an estimated $21.8M.
ADMA Biologics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3563 holding.
Jane Street first reported a position in ADMA Biologics in Q1 2019 and has held it in 26 quarters since.
Jane Street's ADMA Biologics position peaked at $27.5M in Q1 2026.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.